Doctors - Doç.Dr.

Education and Specialization

1997–2005 – Karadeniz Technical University (KTU), Medical Education
2007–2012 – KTU Faculty of Medicine, Department of Internal Medicine — Internal Medicine Specialization / PhD Proficiency / Medical Specialization
2013–2017 – Dokuz Eylul University (DEU) Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology — Subspecialty Training

Experience

04.2007–09.2007 — Physician
Republic of Turkey Ministry of Health, Mus Bulanik Elmakaya Health Center, Mus
2007–2012 — Research Assistant (Internal Medicine)
KTU Faculty of Medicine, Department of Internal Medicine, Trabzon
2013 — Internal Medicine Specialist
Republic of Turkey Ministry of Health, Agri State Hospital, Internal Medicine Clinic, Agri
2013–2017 — Research Assistant (Medical Oncology)
DEU Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Izmir
2018–2019 — Medical Oncology Specialist
Republic of Turkey Ministry of Health, Kanuni Training and Research Hospital, Medical Oncology Clinic, Trabzon
2019–Present — Assistant Professor
KTU Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Trabzon

Membership in Scientific Associations

Trabzon Medical Chamber (since 2007)
Turkish Society of Medical Oncology (since 2014)
Society of Oncology and Immunotherapy (since 2017)

Research and Publications

A. Articles Published in International Peer-Reviewed Journals

A1. Ulusoy S, Ozkan G, Sonmez M, Mungan S, Kaynar K, Cansiz M, Kazaz N. Absence of hypoalbuminemia despite nephrotic proteinuria in focal segmental glomerulosclerosis secondary to polycythemia vera. Internal Medicine, 2010;49(22):2477–2480. DOI:10.2169/internalmedicine.49.4087
A2. Ulusoy S, Ozkan G, Bektas D, Kaynar K, Cansiz M, Kazaz N. Ramsay Hunt syndrome in a renal transplantation recipient: a case report. Transplantation Proceedings, 2010;42(5):1986–1988. DOI:10.1016/j.transproceed.2010.02.078
A3. Ozkan G, Ulusoy S, Kaynar K, Oztuna F, Cansiz M, Kazaz N. Swine H1N1 infection in a renal transplant recipient. Exp Clin Transplant, 2010;8(4):318–320. PMID:21143099
A4. Sonmez M, Kazaz N, Yucel B, Topbas M, Ucar F. C950T and C1181G osteoprotegerin gene polymorphisms… Hematology, 2014;19(4):213–216. DOI:10.1179/1607845413Y.0000000114
A5. Salman T, Kazaz SN, … Prognostic value of the pretreatment NLR and PLR… Chemotherapy, 2016;61(6):281–286. DOI:10.1159/000445045
A6. Atag E, Kazaz SN, … EBV-associated lymphoepithelioma-like carcinoma… J Clin Exp Oncol, 2016;5:6. DOI:10.4172/2324-9110.1000171
A7. Kurt S, Ulukus C, Kazaz SN, Astarcioglu I. Bilateral ovarian metastasis of a Klatskin tumor… Turk J Obstet Gynecol, 2016;13:215–217. DOI:10.4274/tjod.40222
A8. Kazaz SN, Oztop I. Treatment After Crizotinib Resistance in ALK+ NSCLC. UHOD, 2017;27(1). DOI:10.4999/uhod.171786
A9. Kazaz SN, Oztop I. Treatment After First-Generation EGFR TKI Resistance in NSCLC. Turkish Thoracic Journal, 2017;18:66–71. DOI:10.5152/TurkThoracJ.2017.16042
A10. Kazaz SN, Oztop I. Immune Checkpoint Inhibitors in Advanced NSCLC. Turkish Thoracic Journal, 2017;18:101–107. DOI:10.5152/TurkThoracJ.2017.17006
A11. Buyruk AM, Kazaz SN, … NLR, PLR, MPV as biomarkers in early colorectal adenocarcinoma. UHOD, 2017;27(4):220–228. DOI:10.4999/uhod.171711
A12. Atag E, Semiz HS, Kazaz SN, … Response to cabazitaxel beyond 20 cycles… Urology Journal, 2017;14(1):2985–2988. DOI:10.22037/uj.v14i1.3697
A13. Eren H, Aydin HR, … Seher Nazli Kazaz, … Whortleberry protects kidney… 2018;40(1):466–474.
A14. Yildirim S, Kazaz SN, … Information sources of cancer patients’ relatives. J Cancer Educ, 2019;34:913–919.
A15. Atag E, Mutlay F, … Kazaz SN, … Depressive symptoms in elderly cancer patients… 2018;18(5):365–370.
A16. Ilke Onur Kazaz, … Seher Nazli Kazaz, … Bladder metastasis of gastric signet-ring cell carcinoma. Urol Case Rep, 2019;22:62–62.
A17. Ilke Onur Kazaz, … Seher Nazli Kazaz, … Primary renal angiosarcoma… Indian J Pathol Microbiol, 2020;63(5):44–46.
A18. Semiz HS, Kazaz SN, … Prognostic significance of hematological parameters in early melanoma. UHOD, 2020;30(2):103–109.
A19. Ilke Onur Kazaz, … Seher Nazli Kazaz, … Tadalafil and telmisartan in bleomycin-induced pulmonary fibrosis (rat). J Surg Med, 2020;4(8):689–692.
A20. Fidan E, Yildirim A, Kazaz N, … ALBI score and survival in pancreatic cancer. JPMA, 2022;72(7):1340–1344. doi:10.47391/JPMA.2413
A21. Kazaz SN, Yildirim A. COVID-19 knowledge, attitudes, and behaviors among cancer patients. Ann Clin Anal Med, 2022;13(4):389–393.
A22. Aynaci O, Serdar L, … Seher Kazaz, … Radiotherapy during COVID-19: Northeast Turkey 1-year results. Turk J Oncol, 2022;37(2):200–207. doi:10.5505/tjo.2022.3463
A23. S. Disli, E. Fidan, A. Ozdöver, Nazli Kazaz, F. Ozdemir. Complementary/alternative treatment use in breast cancer… Ind J Med Paediatr Oncol, 2022;43:270–277.
A24. E. Fidan, S. Fidan, E. Merev, N. Kazaz. ALBI grade and survival in HCC treated with sorafenib. Niger J Clin Pract, 2022;25(2):173–177.

B. Books / Book Chapters

B1. Textbook of Gastrointestinal Oncology — “Symptom Management…”, Yavuzsen T, Kazaz N, et al. (2019)
B2. Radionuclide Therapy — “Systemic Treatments and Side Effects in Thyroid Cancer”, Seher Nazli Kazaz, Ilhan Oztop (2019)
B3. Radionuclide Therapy — “Systemic Treatments in Neuroendocrine Tumors…”, Seher Nazli Kazaz, Ilhan Oztop (2019)
B4. Turkiye Klinikleri Special Issue—Gynecologic Cancers — “Systemic Therapy in Cervical Cancer” (2019)
B5. Turkiye Klinikleri—Medical Oncology / Lung — “The Future of Lung Cancer Treatment” (2020)
B6. Turkiye Klinikleri—Radiation Oncology — “Adjuvant Therapy in Rectal Cancer” (2020)
B7. Geriatric Oncology — “Assessment Scales in Geriatric Oncology”
B8. Geriatric Oncology — “Tyrosine Kinase Inhibitors in Geriatric Lung Cancer”
B9. Turkiye Klinikleri—ENT—Special Topics — “Chemotherapy in Oral Cavity Cancers”
B10. TTOD—Breast Cancers — “Follow-up and Prognosis in HR+ HER2- Breast Cancer”
B11. Radionuclide Therapy (Springer, 2022) — “Systemic Treatments in Thyroid Cancer”, Ilhan Oztop, Seher Nazli Kazaz
B12. Radionuclide Therapy (Springer, 2022) — “Systemic Treatments in Neuroendocrine Tumors”, Ilhan Oztop, Seher Nazli Kazaz

C. Articles Published in National Peer-Reviewed Journals

C1. Keser M, Kazaz SN, Karaoglu A. Medullary Thyroid Carcinoma. Turkiye Klinikleri J Med Oncol—Special Topics, 2017;10(1):91–96.
C2. Semiz HS, Kazaz N, Karaoglu A. Adjuvant/Neoadjuvant Systemic Therapy in Lung Cancer. Turkiye Klinikleri J Thor Surg—Special Topics, 2017;8(1):264–271.
C3. Celal Alandas, Seher Nazli Kazaz, Bengu Cobanoglu. Adenoid Cystic Carcinoma; 15-Year Single-Center Experience. EJMI, 2021;5(4):491–495.

D. Papers Presented at International Scientific Meetings (Selection)

D1. Sonmez M, Kazaz N, … OPG gene polymorphisms and myeloma bone disease. ASH 2013, New Orleans — Blood 2013;122:3128
D2–D8. Case/report series in collaboration with DEU and Izmir Oncology Group on GIS and colon cancers (2014, Istanbul)

E. Papers Presented at National Scientific Meetings (Selection)

E1–E3. Nephrology/Transplant papers (2010)
E4. Early leukocyte decrease and prognosis after chemotherapy in AML (2012)
E5–E25. Geriatric oncology, rare tumors, GIS and colon cancer reports (2014–2015)
E26–E33. Breast, melanoma, lung, immunotherapy reports (2015–2016)
E34–E38. Immuno-oncology, rare lung tumors, case series (2016–2021)

Participation as Speaker

2016–2022: Numerous conferences including “Perspectives in Oncology”, “Geriatric Oncology”, “Uro-oncology”, TTOK, TAKD, etc., as speaker / session chair (topics: immunotherapy side-effect management, targeted therapies, mCRC sequencing, NSCLC biomarkers, perioperative treatments, etc.)

Course Participation

2004 – Rational Drug Selection and Use (KTU)
2009 – Kidney Transplant Pathology (KTU)
2014–2017 – TTOD Update Courses (Head-Neck, CNS, Sarcomas, Basic Oncology)
2015 – “Diagnosis–Treatment–Management in Metastatic Colorectal Cancer”, Oldenburg/Germany
2019 – KTU Clinical Research Center Good Clinical Practice (GCP) Certificate
2021 – “Advances in Hormone Therapy in Prostate Cancer” (Speaker)

Congress Participation

Between 2009–2022: attended National Cancer Congresses, ASCO, ESMO, EMUC, St. Gallen, EIKCS, national immunotherapy/oncology congresses, and regional symposiums (on-site and e-congress)